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SUMMARY
Neuroblastoma is a rare developmental tumour of young children accounting for a disproportionally high 
proportion of paediatric cancer deaths. Increasing insights into neuroblastoma genetics and biology led to 
the identification of the MDM2 antagonist idasanutlin as a promising therapeutic strategy. In this thesis, we 
investigated two key aspects that could facilitate the clinical implementation of idasanutlin for the treatment 
of neuroblastoma patients. First, we identified the BCL2 inhibitor venetoclax as a synergistic drug partner of 
idasanutlin using both in vitro and in vivo model systems of neuroblastoma. Second, we discovered circula-
ting miRNAs that dynamically respond to p53 activation in mice carrying human neuroblastoma xenografts; 
opening up possibilities for non-invasive treatment monitoring.
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INTRODUCTION
Neuroblastoma is the second most common solid cancer in 
childhood and is a complex and heterogeneous disease.1 In 
spite of significant improvement in overall survival rates in 
the last decade, a considerable group of high-risk patients 
have shown only modest improvement. A distinct feature 
of neuroblastoma is that despite a low (<2%) frequency of 
mutations in the TP53 tumour suppressor gene, proper p53 
functioning is compromised, primarily due to an augment-
ed activity of its principal negative regulator, MDM2.1,2 The 
impairment of intrinsically intact p53 protein by MDM2 in 
neuroblastoma tumours offers an attractive therapeutic op-
portunity. MDM2 antagonists like nutlin-3a and idasanutlin 
reactivate p53 and have proven to exhibit potent anti-tumour 
effects in neuroblastoma cells using both in vitro and in vivo 
model systems.3-5 Recently, idasanutlin and other latest-gen-
eration MDM2 inhibitors have reached clinical development 
for several adult cancer types. This thesis aimed to investigate 
two strategic aspects that could facilitate the development of 
idasanutlin for the treatment of neuroblastoma patients: the 
identification of synergist drug partners and the identifica-
tion of non-invasive biomarkers for treatment response. 
SEEKING SYNERGY
A main requisite for the successful introduction of novel tar-
geted drugs in the clinic is the identification of well-matched 
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drugs for combination therapy. Ideally these combinations 
allow higher clinical efficacy, limit toxicity and prevent 
treatment resistance. To identify targeted drugs that could 
potentiate the anti-tumour effects of idasanutlin, fifteen tar-
geted drugs were evaluated in combination with idasanut-
lin in neuroblastoma cells.6 The highest degree of synergism 
was observed when idasanutlin was combined with ABT-
263, an inhibitor of the anti-apoptotic proteins BCL2 and 
BCL-XL. When idasanutlin was combined with the more se-
lective BCL2 inhibitor ABT-199 (venetoclax), a comparable 
strong synergistic activity was recorded, irrespective of bas-
al BCL2 and MCL1 expression levels. In neuroblastoma cells, 
the combination therapy resulted in increased induction of 
apoptosis compared to either treatment alone, consistent with 
the proposed mechanism of action of both targeted drugs. In 
addition, when evaluated in nude mice carrying orthotopic 
xenografts of human neuroblastoma cells, the combination 
of idasanutlin and venetoclax was significantly more effec-
tive than either treatment alone without an increased occur-
rence of adverse events.
SEEKING NON-INVASIVE BIOMARKERS 
Accurate assessment of treatment response and residual dis-
ease is indispensable for the evaluation of cancer treatment 
efficacy. Novel, non-invasive biomarkers that allow moni-
toring of tumour burden and response to treatment are 
therefore highly desirable. MicroRNAs (miRNAs), a class of 
small non-coding RNAs that regulate gene expression at the 
post-transcriptional level, are deregulated in various cancer 
types including neuroblastoma and have recently emerged as 
promising circulating biomarkers.7-10 It was therefore evaluat-
ed whether miRNAs are suitable to monitor neuroblastoma 
tumour burden and whether treatment-induced changes of 
miRNA abundance in the tumour are reflected in the serum. 
Therefore, small RNA sequencing was optimised for opti-
mal performance on murine serum and consecutively per-
formed on longitudinally collected serum samples obtained 
from nude mice carrying orthotopic neuroblastoma xeno-
grafts that had been exposed to treatment with idasanutlin or 
the rapamycin-derived mTOR inhibitor temsirolimus or vehi-
cle control.11,12 Fifty six serum miRNAs were found to be dif-
ferentially expressed upon xenograft tumour manifestation. 
Evaluation of these 56 miRNAs in serum pools collected from 
healthy children and children suffering from high-risk neuro-
blastoma showed that twenty of these miRNAs were also spe-
cifically expressed in the serum of high-risk neuroblastoma 
patients. In mice, the serum levels of these 56 miRNAs cor-
related with both tumour tissue expression and tumour size, 
suggesting potential utility for monitoring of tumour burden. 
In addition, idasanutlin-induced serum miRNA expression 
changes were identified one day after the start of treatment 
and on day eleven of treatment. By limiting miRNAs with a 
tumour-related induction, hsa-miR-34a-5p/mmu-miR-34a-
5p and hsa-miR-212-3p/mmu-miR-212-3p were put forward 
as potential biomarkers of p53 activation in serum. 
CONCLUSIONS
The findings presented in this thesis point to the BCL2 in-
hibitor venetoclax as a strongly synergistic drug partner of 
idasanutlin, enabling an increased therapeutic efficacy in 
both in vitro and in vivo model systems of neuroblastoma. In 
addition, circulating miRNAs correlating with tumour bur-
den and dynamically responsive to targeted p53 reactiva-
tion were identified. In conclusion, these findings provide 
a relevant contribution to the development of idasanutlin as 
an efficient therapeutic strategy for children suffering from 
neuroblastoma.
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ONCOTHESIS
KEY MESSAGES FOR CLINICAL PRACTICE
1.  Increasing insights in neuroblastoma biology have led to the identification of the MDM2 antagonist 
idasanutlin as a promising therapeutic approach for treating neuroblastoma patients.
2.  Concomitant targeting of BCL2 by venetoclax potentiates the anti-tumour effects of idasanutlin.
3.  Circulating miRNAs may provide an elegant non-invasive approach for monitoring disease progression 
and treatment response in patients carrying solid tumours.
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